BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

LuMend Focused On Rapidly Growing Peripheral Vascular Market


10/19/2005 5:11:35 PM

REDWOOD CITY, Calif., June 2 /PRNewswire/ -- LuMend Inc., a leader in developing solutions to treat chronic total occlusions (CTO), is launching the Frontrunner XP CTO Catheter platform as part of their new peripheral vascular strategic initiatives. The XP family of catheters is based on the highly successful Frontrunner X39 coronary CTO Catheter and is designed to provide enhanced performance in crossing occlusions in the peripheral vasculature. The Frontrunner family of products utilizes a proprietary blunt micro dissection technology to improve the physician's ability to cross CTOs.

The new 4.5 french Frontrunner XP CTO Catheter is designed to address the unique demands associated with the specific anatomical and lesion characteristics often found in the peripheral vasculature. The XP, which can be delivered through a 6 french guide catheter, incorporates a more flexible shaft designed to optimize delivery performance, enhanced tip shape-ability and an improved polymer formulation designed to improve handling and crossing performance. The Frontrunner XP Catheter is available in both 90cm and 140cm lengths to accommodate various patient anatomies and procedural approaches.

"One of the barriers to continuing expansion of catheter based approaches to treating peripheral vascular disease is the high incidence of CTOs in these vessels," stated John Paul Runyon, M.D., an interventional cardiologist from Christ Hospital in Cincinnati, Ohio. "CTOs remain the leading cause for surgical bypass in peripheral vascular disease and are a leading cause of critical limb ischemia and resulting amputations. CTOs in the peripheral anatomy can be 100mm to 300mm in length and these long occlusions, especially those with severe calcification or plaque deposits, present additional technical and clinical challenges for the interventional practitioner. LuMend has dramatically enhanced the Frontrunner device's ability to quickly and successfully cross these long CTOs. Lesions that were considered untreatable via existing percutaneous methods can now be reconsidered in light of the excellent performance of the Frontrunner XP. This new platform has the potential to provide tremendous clinical benefit to the patient, time savings for the physician and cost-savings to the hospital."

"There are a multitude of new therapies evolving to treat the enormous population affected by peripheral vascular disease," stated Phil Hopper, President and CEO of LuMend. "However, in order for these emerging technologies to be successful a conventional guide wire must first be placed across the CTO. This is where the Frontrunner XP adds tremendous value. LuMend creates the path for others to follow."

LuMend, Inc. was co-founded in 1996 by pioneering interventional cardiologists, John Simpson, M.D., Ph.D., and Matt Selmon, M.D. to provide a catheter based clinical solution to chronic total occlusions The initial focus of the company's efforts were in the coronary vasculature. The U.S. Food and Drug Administration (FDA) granted an expanded indication for the original Frontrunner CTO Catheter for use in the peripheral vasculature in January 2003. This expanded indication, early clinician feedback on the use of the product in the peripheral vasculature, and the pervasiveness of the CTO problem in peripheral procedures prompted the company to re-evaluate their original coronary strategy.

In early 2004, LuMend changed its strategic direction and began to focus on developing product platforms that target CTOs in the rapidly growing peripheral vascular market. Consistent with the company's new strategy, LuMend and Abbott Laboratories recently agreed to the termination of their agreement, which had provided Abbott Vascular an exclusive license to LuMend technology used in the peripheral vasculature.

As a result of this strategic shift, LuMend restructured its in-house and sales organizations. The company continues to manufacture, sell, and support the original Frontrunner X39 coronary CTO Catheter to those utilizing the technology to facilitate crossing CTOs in the coronary vasculature. The focus of the organization, however, has now changed to delivering technology and services to interventional cardiologists, radiologists, and vascular surgeons specializing in endovascular techniques for the treatment of peripheral vascular disease.

LuMend, Inc. is located in Redwood City, California. For more information, visit the company's website at http://www.lumend.com/ or email at info@lumend.com.

LuMend, Inc.

CONTACT: Steve Moscaret, Vice President, Sales & Marketing of LuMend,Inc., +1-650-817-8232



Read at BioSpace.com

LuMend
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES